Defunct Company
Total Trials
8
As Lead Sponsor
2
As Collaborator
6
Total Enrollment
5,479
NCT00578240
Molecular Studies and Clinical Correlations in Human Prostatic Disease
Phase: N/A
Role: Collaborator
Start: Apr 30, 1990
Completion: Dec 31, 2026
NCT00210470
A Phase 2 Clinical Trial of the Safety and Effects of IRX-2 in Treating Patients With Operable Head and Neck Cancer
Phase: Phase 2
Role: Lead Sponsor
Start: Jul 31, 2005
Completion: Mar 31, 2012
NCT02609386
IRX-2 Regimen in Patients With Newly Diagnosed Stage II, III, or IVA Squamous Cell Carcinoma of the Oral Cavity
Start: Jan 11, 2016
Completion: Feb 28, 2022
NCT02950259
Pre-operative IRX-2 in Early Stage Breast Cancer (ESBC)
Phase: Phase 1
Start: Feb 9, 2017
Completion: Dec 31, 2025
NCT03267680
IRX-2 Regimen in Treating Women With Cervical Squamous Intraepithelial Neoplasia 3 or Squamous Vulvar Intraepithelial Neoplasia 3
Start: Nov 8, 2017
Completion: Mar 13, 2024
NCT03381183
IRX-2 Regimen and Durvalumab, for Incurable H&N Squamous Cell Carcinoma
Start: Aug 21, 2019
Completion: Jun 30, 2023
NCT03575234
Nivolumab & IRX-2 With Surgery for Resectable Stage III-IVA Oral Cavity Cancer or HPV-Positive Oropharyngeal Cancer
Start: Jul 1, 2020
Completion: Jan 31, 2026
NCT04373031
Pembrolizumab, IRX-2, and Chemotherapy in Triple Negative Breast Cancer
Start: Dec 30, 2020